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Rhythm 2014;11:911–21.REPLY: Differences in Experience With a
New Delivery Device for LAA Ligation
Among Various U.S. CentersWe thank Dr. Rasekh and colleagues for their interest
in our multicenter study of transcatheter left atrial
appendage (LAA) closure with the Lariat suture de-
livery device (SentreHeart, Redwood City, California)
(1). They cite concerns about the participating
centers, operator training, and inclusion criteria,
and claim that our study “shows how a procedure
can have suboptimal outcomes if not executed
properly.” However, this assertion is without merit.
At time of the conception of the registry, all U.S.
sites that were performing the Lariat procedure were
identiﬁed with the assistance of the manufacturer
and invited to participate. Centers that collaborated
in data sharing and provided complete data sets were
included. We ﬁnd it intriguing that the authors are
critical of our site selection, yet were invited to
participate and declined (A.R., S.K., A.M., and D.L.),
with the exception of the University of California-San
Francisco (N.B.), which was not included because of
perceived conﬂicts of interest.
All procedures followed the manufacturer’s pro-
tocols. The manufacturer reviewed all cardiac computed
tomograms before the procedure to conﬁrm anatomic
eligibility according to their pre-deﬁned speciﬁcations.
A clinical specialist or other representative employed by
the manufacturer was present during all procedures.
Reﬂecting their technical skill set, several of the opera-
tors involved in the study served as proctors for the
procedure at the request of the manufacturer.
Our registry included, by design, early procedural
experience; proﬁciency may improve with ongoingcollective experience. There was no signiﬁcant rela-
tionship between site volume and procedural success,
and the inclusion of low volume sites cannot fully
explain our ﬁndings.
Dr. Rasekh and colleagues further assert that our
ﬁndings are inconsistent with the clinical experience
of other operators. Since our publication, another
multicenter study has reported safety and efﬁcacy
event rates similar to that of our study, thereby sup-
porting our overall conclusions (2). Dr. Rasekh and
colleagues cite their own “quick survey” that they
claim shows a substantially better safety proﬁle with
the Lariat. The methodological soundness of an
informal survey is unclear, and their ﬁndings must
be subject to peer review before they can be
considered valid. We commend the authors for their
attempt to systematically collect data and look
forward to the publication of their ﬁndings.
Although we observed very high rates of technical
success, our study raises questions about the safety
and the efﬁcacy of the procedure. The authors argue
that safety can largely be addressed with the use of a
micropuncture needle for pericardial access. How-
ever, this would only affect the risk of right ven-
tricular (RV) perforation. Just one-quarter of the
pericardial effusions that occurred in our report were
felt to be secondary to pericardial sheath placement.
Of the 34 adverse events (including several deaths)
associated with the Lariat that were reported in the
Food and Drug Administration MAUDE (Manufacturer
and User Facility Device Experience) database
between January 2012 and April 2014, only 2 were
attributed to RV perforation; the remainder were
LAA perforations, lacerations, or avulsions (3).
Improving pericardial access would not inﬂuence
the incidence of important post-procedural adverse
events, such as stump thrombus, pleural effusion,
and stroke.
The authors correctly state that our study en-
compasses only a fraction of the >2,000 patients
who have been treated with the Lariat. Regrettably,
our small study of 154 patients represents approxi-
mately one-half of the entire peer-reviewed data
set for a device that is being used in the absence of
any clinical trial or a Food and Drug Administration-
approved indication for stroke prevention; however,
it may be associated with substantial morbidity.
A multicenter, randomized trial with independent
oversight is urgently needed to robustly deﬁne the
safety and long-term efﬁcacy of transcatheter LAA
ligation.*Matthew J. Price, MD
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the Real Cause of Most
Sudden Deaths in Athletes?I read with interest and great concern the report by
Yankelson et al. (1) on heat stroke and sudden cardiac
arrest (SCA) or death (SCD) during endurance
sports. The investigators reported the results of
their retrospective study of 137,580 marathon
runners in Israel and concluded that: 1) marathon
runners who die during competition are more often
the victims of fatal heat stroke than of cardiac
events, and 2) core body temperature (CBT) should
be consistently monitored in endurance athletes as
a fundamental risk factor, because a CBT >40C
alone should be considered sufﬁcient to cause
sudden death.
The evidence presented in the study does not
appear to support either conclusion. The few
observed events were superﬁcially described (e.g., no
autopsy ﬁndings were reported for the 2 runners
who died of heat stroke). Although the investigators
claimed that measuring CBT is critical to diagnosing
heat stroke, adequate CBT data were not reported
for a comprehensive group of their cohort of
runners. Also, it did not appear that possible alter-
native causes (primarily cardiovascular-related)
of or contributing factors in SCD were ruled out.
Strenuous exercise is known to generically increase
CBT and is accompanied by the production ofinﬂammatory cytokines (2). This being the case, the
absence of control data from runners who had no
adverse events (who constituted the majority of the
runners, and who were subject to the same con-
ditions of workload and environmental temperature
as the runners who had adverse events) seems
especially important; without such data, it is
difﬁcult to determine whether there is a “critical
CBT” above which adverse events are likely to
occur. Accurate, routine pre-certiﬁcation protocols
(3) were not required or used in the majority of
runners in this cohort, so the prevalence of high-
risk cardiovascular conditions (hr-CVC) in the
participant runners (and the consequent risk of SCD)
was not known.
In contemplating the implications of the ﬁndings by
Yankelson et al. (1), it is important to consider that
although few runners experience SCD, high CBT is
essentially related to workload (2) and environmental
factors that are common to all runners. Furthermore,
runners who have hr-CVC may have a greater-
than-normal risk of developing high CBT due to the
onset of cardiovascular failure. (Low cardiac
output and heart failure, which last for some time
after the onset of cardiac decompensation, generally
lead to inefﬁcient breathing and heat dispersion.)
Athletic competition, by its very nature, encourages
participants to perform at their physical limits;
among competitors who have hr-CVC, CBT probably
becomes substantially higher than that of their peers.
In such cases, hr-CVC would be the primary cause of
SCA, not a secondarily high CBT.
Although the CBT story is both interesting
and puzzling, and although we await more solid data
about this parameter in a sizeable sample of en-
durance runners, we should strive to eliminate the
inconvenience and impracticality of using
rectal temperature measurements in the usual urban
environment of marathons. Acceptable alternative
devices other than implantable esophageal
or intestinal probes, such as infrared laser ear-
lobe thermometers, already exist and could easily be
made available at these races (4,5). Although
CBT is higher than cutaneous temperature, the 2
measurements are correlated (and both temp-
eratures increase with exertion [4,5]), and it is likely
that a convenient compromise between optimal pre-
cision and clinical relevance could be found.
I appreciate the interest of my colleagues in this
important aspect of exercise pathophysiology and
would encourage them to continue their important
study of a potentially easily preventable cause of
sudden death during sports. At the same time, the
focus on temperature should not distract from the
